Vial Announces $67M Series B Led by General Catalyst
Read Vial's feature in the WSJ

The Oncology CRO
Built for Sponsors,
Powered by Technology

Reimagined clinical trials delivering faster and more efficient trials for sponsors

Our Oncology CRO Executive Team

Our Oncology CRO team has extensive experience leading CROs across indications

Our experienced CRO executive team works closely with our expert site operations team to continuously review execution strategies, closely monitor patient recruitment efforts, and mitigate key study risks for Oncology clinical trials.

Wendy Pinson

Wendy
Pinson

Director of Oncology

More than 14 years in the biopharma clinical research industry. Leader in clinical operations across oncology, rare disease, GI, infectious disease, autoimmune, OB/GYN, and more.

Connect with Wendy

Richard McCormick Jr.

VP of Oncology

Prominent leader, clinical operations and project management professional with 20+ years of experience specializing in hematology and oncology indications to support complex oncology research for biotech clients.

Powered By Our Connected Technology Platform

Vial CRO delivers faster, more efficient trials
by empowering phenomenal clinical operators
with powerful technology

Vial’s modern technology platform brings clinical trials out of the paper stone age, allowing for streamlined processes inside one end-to-end system.

NGS Integrations

Integrations with leading NGS providers and multi-omics vendors to support targeted oncology sponsors.

No-Nonsense Pricing

Vial offers sponsors fixed-pricing
agreements with no change orders — ever.

Flat-rate pricing

Zero change orders

Risk-share
on commitments

Accountability
on commitments

A fixed-fee pricing model guarantees a set budget for the entirety of a project, regardless of the time and expense that accrues. Vial reserves the right to modify pricing in accordance with amendments to the study design or protocol.

Vial offers fixed upfront pricing to benefit sponsors:

  • Align Incentives
  • Transparent budget visibility
  • No unexpected charges/fees
  • Shared accountability on commitments
  • Build trust and deepen the relationship
  • Experienced team committed to timelines
  • Next-generation technology to streamline workflows and process
  • A renowned scientific advisory board providing expert insight
  • Deep industry relationships and a preferred site network provide an insider view on trial pain points, allowing us to target and prepare to prevent common errors or delays

Tech-Enabled Recruiting Platform

Accelerate Patient Recruiting
Using Multi-Channel Marketing Strategies
and Powerful Technology

vial
vial

We use the most effective digital tools to reach, screen, and enroll motivated subjects quicker. Our optimized process can cut recruitment times in half.

EMR Integrations

HIPAA compliant automated data pulls and Inclusion/Exclusion reviews.

Fast Start-up and Consolidated Site Activation

Vial onboarded 90% of our sites
in less than 30 days

Between our robust technology platform and our team of expert operators, we cut onboarding times in half at nearly every site.

Scientific Advisory Board

Vial CRO is supported by a team of Scientific Advisors who review and provide input on the strategy and direction of the CRO in order to build the infrastructure to advance Oncology research.

Bladder Cancer Director at the Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School View Profile
Professor of Medicine and Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute, University of Utah View Profile
CEO at Urology Cancer Center and XCancer Research View Profile
Director of Summit Cancer Centers, Medical Oncologist View Profile
Head of Clinical Development at PACT Pharma View Profile
Professor of Medicine, Professor of Surgery, and Professor of Molecular and Medical Pharmacology at the University of California Los Angeles (UCLA) View Profile

Experience across
Immuno-Oncology

The Vial Oncology CRO is supported by a team of scientific advisors with expertise across therapies in immuno-oncology. These advisors provide input on the strategy and direction of the CRO in order to build the infrastructure to advance the research of monoclonal antibodies.

Dr. Neeraj Agarwal

Professor of Medicine and Presidential Endowed Chair of Cancer Research
at the Huntsman Cancer Institute, University of Utah

Dr. Guru Sonpavde

Bladder Cancer Director at the Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard
Medical School

The Vial Oncology CRO is supported by a team of scientific advisors with expertise across therapies in immuno-oncology. These advisors provide input on the strategy and direction of the CRO in order to build the infrastructure to advance the research of cell therapies.

Dr. Arati Rao

Head of Clinical Development at PACT Pharma

The Vial Oncology CRO is supported by a team of scientific advisors with expertise across therapies in immuno-oncology. These advisors provide input on the strategy and direction of the CRO in order to build the infrastructure to advance the research of checkpoint inhibitors.

Dr. Antoni Ribas

Professor of Medicine, Professor of Surgery, and Professor of Molecular and Medical Pharmacology at the University of California Los Angeles (UCLA)

Dr. Guru Sonpavde

Bladder Cancer Director at the Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard
Medical School

Dr. Nathan Pennell

Professor of Medicine and the Director of the Lung Cancer Medical Oncology Program at the Cleveland Clinic Taussig Cancer Institute

Dr. Brian Rini

Chief of Clinical Trials and Professor of Medicine at Vanderbilt University

The Vial Oncology CRO is supported by a team of scientific advisors with expertise across therapies in immuno-oncology. These advisors provide input on the strategy and direction of the CRO in order to build the infrastructure to advance the research of cancer vaccines.

Dr. Guru Sonpavde

Bladder Cancer Director at the Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard
Medical School

Dr. Eric Jonasch

Genitourinary Medical Oncology Professor and Physician at The University of Texas MD Anderson Cancer Center

Upcoming Events

Vial will be at the 64th ASH Annual Meeting
Vial is proud to attend the 64th American Society of Hematology Annual Meeting.

Past Events

DPHARM Vial will be at the SITC 37th Annual Meeting
Vial is proud to be an exhibitor at the Society for Immunotherapy of Cancer 37th Annual Meeting. Come visit us at Booth #645.
Vial will be at WIN Symposium 2022
Vial is proud to attend the WIN 2022 Symposium.
Vial will be at ENA 2022 34th Symposium
Vial is proud to attend ENA 2022; the EORTC NCI AACR 34th Symposium.
White Paper

Tech-Enabled Remote Monitoring Part 1

Download our white paper to learn more about each stakeholder’s benefits of tech-enabled trials.

White Paper

Tech-Enabled Remote Monitoring Part 2

Download our white paper to learn more about each stakeholder’s benefits of tech-enabled trials.

White Paper

Vial’s Deployment of Modern, Intuitive Electronic Source

Download our latest white paper to learn how utilizing eSource in clinical trials can streamline process, increase efficiency, and minimize errors.

Press Releases

Vial to Launch Oncology CRO, Arati Rao, M.D. named as First Advisor

White Paper

Tech-Enabled Remote Monitoring Part 1

Articles

Vial Launches VialConnect: a Modernized CTMS with Patient Recruitment Assistance

oncology cro

Why Choose Vial's Oncology CRO?

Streamlined oncology clinical trial startup, more predictable patient recruitment, and higher-quality data.

Vial leverages the expertise and abilities of our in-house oncologists and clinical delivery experts to offer oncology sponsors a CRO built for their greatest needs. Vial’s tech-enabled trial management system and seamless operating system ensure that trials are run with maximum efficiency.

We have thoughtfully built our scientific advisory board to include research experienced oncologists who not only have a passion for new oncology therapies, but also an understanding of how to harness the power of precision medicine and clinical data to combat the growing complexity of oncology clinical trials.

Indications

Broad Experience Across Oncology Indications and Phases

Connect with us.

Interested in receiving a proposal from Vial? Leave us a message and some of your contact info and we’ll be in touch with you shortly.

If you’re looking to participate in a clinical trial, please click here

Contact Us

Note: If you are looking to participate in a clinical trial, please click here
Name(Required)
By submitting, you are agreeing to our terms and privacy policy
This field is for validation purposes and should be left unchanged.